CytomX Therapeutics Operating Income 2014-2022 | CTMX
CytomX Therapeutics operating income from 2014 to 2022. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
CytomX Therapeutics Annual Operating Income
(Millions of US $) |
| 2021 |
$-84 |
| 2020 |
$-49 |
| 2019 |
$-111 |
| 2018 |
$-78 |
| 2017 |
$-46 |
| 2016 |
$-60 |
| 2015 |
$-33 |
| 2014 |
$-30 |
| 2013 |
$-15 |
CytomX Therapeutics Quarterly Operating Income
(Millions of US $) |
| 2022-03-31 |
$-24 |
| 2021-12-31 |
$-26 |
| 2021-09-30 |
$-23 |
| 2021-06-30 |
$-19 |
| 2021-03-31 |
$-16 |
| 2020-12-31 |
$-15 |
| 2020-09-30 |
$-15 |
| 2020-06-30 |
$-16 |
| 2020-03-31 |
$-3 |
| 2019-12-31 |
$-37 |
| 2019-09-30 |
$-26 |
| 2019-06-30 |
$-31 |
| 2019-03-31 |
$-17 |
| 2018-12-31 |
$-26 |
| 2018-09-30 |
$-23 |
| 2018-06-30 |
$-13 |
| 2018-03-31 |
$-16 |
| 2017-12-31 |
$-1 |
| 2017-09-30 |
$-11 |
| 2017-06-30 |
$-25 |
| 2017-03-31 |
$-9 |
| 2016-12-31 |
$-14 |
| 2016-09-30 |
$-15 |
| 2016-06-30 |
$-14 |
| 2016-03-31 |
$-16 |
| 2015-12-31 |
$-12 |
| 2015-09-30 |
$-11 |
| 2015-06-30 |
$-6 |
| 2015-03-31 |
$-5 |
| 2014-12-31 |
|
| 2014-09-30 |
$-3 |
| 2013-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.106B |
$0.070B |
|
CytomX Therapeutics, Inc. is an oncology focused biopharmaceutical company. The Company is engaged in developing Probody(TM) therapeutics for the treatment of cancer. Its pipeline focuses areas consist of Precision cancer immunotherapy and Probody drug conjugates. CytomX Therapeutics, Inc. is headquartered in South San Francisco, California.
|
